Clinical Trials Logo

Clinical Trial Summary

The goal of this qualitative study is to explore influencing factors for physical activity participation in people affected by an advanced head and neck cancer from the perspective of people affected and their significant others. Individual interviews will be conducted with people affected by head and neck cancer and focus group interviews will be held with significant others of people being affected to answer the following research questions: - What capabilities and opportunities for physical activity participation do people with advanced head and neck cancer experience? - What motivates people with advanced head and neck cancer to be physically active? - How do significant others view capabilities, opportunities, and motivation for physical activity participation in people with head and neck cancer? The interviews will be transcribed verbatim and analysed with a structuring content analysis approach.


Clinical Trial Description

see attached study protocol ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06272513
Study type Observational
Source Kantonsspital Winterthur KSW
Contact Martina Schmocker, MSc
Phone +41 52 266 55 68
Email martina.schmocker@uzh.ch
Status Not yet recruiting
Phase
Start date March 2024
Completion date June 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05039801 - IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Phase 1
Recruiting NCT05050162 - Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer Phase 2/Phase 3
Active, not recruiting NCT05057247 - Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC Phase 2
Withdrawn NCT05743777 - PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Terminated NCT03254927 - A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Active, not recruiting NCT05383170 - A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers Phase 1/Phase 2
Suspended NCT04454489 - Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition Phase 2
Recruiting NCT02955290 - CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer Phase 1/Phase 2
Recruiting NCT04533750 - Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin Phase 1